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CEF  
SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 310 (FGE.310): 
Rebaudioside A from chemical group 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate rebaudioside A [FL-no: 16.113], a steviol glycoside. 
The substance was not considered to have genotoxic potential. Since a comprehensive and adequate 
toxicological database, including human studies, is available for steviol glycosides, the Panel based its 
evaluation of rebaudioside A on a comparison of the ADI of 4 mg/kg bw, expressed as steviol, 
established by EFSA, with the estimated dietary exposure figures based on the MSDI and mTAMDI 
approaches. The Panel concluded that rebaudioside A [FL-no: 16.113] would not give rise to safety 
concerns at the estimated level of intake arising from its use as flavouring substance. 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate one flavouring substance in the 
Flavouring Group Evaluation 310, using the Procedure as referred to in the Commission Regulation 
(EC) No 1565/2000. This flavouring substance belongs to chemical group 30, Annex I of the 
Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation deals with the steviol glycoside rebaudioside A [FL-no: 
16.113].  
It has been reported that the flavouring substance occurs naturally in Stevia rebaudiana, up to 16200 – 
72700 mg/kg, depending on plant species. 
The flavouring substance is included in the specifications for the food additive (sweetener) steviol 
glycosides which has recently been evaluated by both the JECFA (JECFA, 2009a) and EFSA (EFSA, 
2010k). The flavouring substance rebaudioside A [FL-no: 16.113] is closely related structurally to 
stevioside. Both compounds contain the same aglycon steviol, the only difference being that 
rebaudioside A contains an extra glucose molecule in the glycoside moiety. Steviol glycosides are 
chemically defined mixtures that comprise not less than 95 % stevioside and/or rebaudioside A. Both 
the JECFA and EFSA established an ADI for steviol glycosides (including rebaudioside A), expressed 
as steviol equivalents, of 4 mg/kg bw/day. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
Overall, stevioside and rebaudioside A do not show evidence of genotoxicity in vitro or in vivo. 
Because a comprehensive and adequate toxicological database, including human studies, is available 
for steviol glycosides the candidate substance rebaudioside A [FL-no: 16.113] should not be evaluated 
using the Procedure as referred to in the Commission Regulation EC No 1565/2000 (EC, 2000a). 
Instead the Panel based its evaluation on a comparison of the ADI of 4 mg/kg bw, expressed as steviol, 
established by EFSA (EFSA, 2010k) with the estimated MSDI and mTAMDI values. 
According to the default MSDI approach, the substance has a daily per capita intake as a flavouring of 
1200 microgram/capita/day. The MSDI of 1200 microgram rebaudioside A/capita/day, equivalent to 
20 microgram rebaudioside A/kg bw/day, for a person weighing 60 kg, corresponding to a daily intake 
of 6.6 microgram steviol/kg bw/day, using a conversion factor of 0.33 (EFSA, 2010k) for converting 
the amount of rebaudioside A into steviol equivalents. This intake, as a flavouring substance, amounts 
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to 0.17 % of the ADI of 4 mg/kg bw, expressed as steviol, established by EFSA (EFSA, 2010k). The 
Panel concluded that rebaudioside A [FL-no: 16.113] does not pose a safety concern when used as 
flavouring substance at the estimated level of intake, based on the MSDI approach. 
The estimated intake of the candidate substance rebaudioside A [FL-no: 16.113] based on the 
mTAMDI is 10888 microgram/person/day, is equivalent to 181 microgram rebaudioside A/kg bw/day, 
for a person weighing 60 kg. This correspond to a daily intake of 60 microgram steviol/kg bw/day, 
using a conversion factor of 0.33 (EFSA, 2010k) for converting the amount of rebaudioside A into 
steviol equivalents. This intake amounts to 1.5 % of the ADI of 4 mg/kg bw, expressed as steviol, 
established by EFSA (EFSA, 2010k). The Panel concluded that rebaudioside A [FL-no: 16.113] does 
not pose a safety concern when used as flavouring substance at the estimated level of intake, based on 
the mTAMDI approach. 
Steviol glycosides are (expected to be) authorised as food additives in the EU. The Panel noted that in 
its recent evaluation the EFSA ANS Panel estimated the potential exposure to steviol glycosides from 
use as food additives. When considering the proposed maximum use levels as food additive, the mean 
dietary exposure to steviol glycosides expressed as steviol equivalents in European children might 
exceed the ADI of 4 mg/kg bw/day. Thus, the estimated intake of rebaudioside A [FL-no: 16.113] 
from its use as a flavouring substance contributes to the total intake of steviol glycosides. 
In order to determine whether the conclusion for the flavouring substance can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
the flavouring substance rebaudioside A [FL-no: 16.113]. 
The Panel concluded that on the basis of the default MSDI approach and the mTAMDI approach, 
rebaudioside A [FL-no: 16.113] would not give rise to safety concerns at the estimated level of 
intake arising from its use as flavouring substance. 
KEYWORDS 
Rebaudioside A, steviol glycosides, diterpene, flavouring, safety, FGE.310.  
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BACKGROUND 1 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 2 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 3 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 4 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 5 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 6 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 7 
divided into 34 chemical groups. Substances within a group should have some metabolic and 8 
biological behaviour in common. 9 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 10 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 11 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 12 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 13 
2002b).  14 
After the completion of the evaluation programme the Union List of flavouring substances for use in 15 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 16 
TERMS OF REFERENCE 17 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 18 
substances in the Register prior to their authorisation and inclusion in a Community List according to 19 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 20 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 21 
evaluation programme. 22 
In addition, in letter of 28 January 2010 the Commission requested EFSA to carry out a risk 23 
assessment on rebaudioside A [FL-no: 16.113] in accordance with Commission Regulation (EC) No 24 
1565/2000 (EC, 2000a): 25 
“The European Commission requests the European Food Safety Authority to carry out a safety 26 
assessment on eighteen new flavouring substances in accordance with Commission Regulation (EC) 27 
No 1565/2000 (EC, 2000a) by end 2010”, if possible by the end of the authorisation programme, if not 28 
within nine months from the finalisation of the programme.”   29 
The deadline of the Terms of Reference for rebaudioside A [FL-no: 16.113] was negotiated to 31 May 30 
2011. 31 
The remaining substances of this request were evaluated in other FGEs. 32 
ASSESSMENT 33 
1. Presentation of the Substances in Flavouring Group Evaluation 310 34 
1.1. Description 35 
The present Flavouring Group Evaluation 310, deals with one steviol glycoside from chemical group 36 
30, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). The flavouring substance 37 
rebaudioside A [FL-no: 16.113] (candidate substance) is covered by the specifications for the food 38 
additive (sweetener) steviol glycosides which has recently been evaluated by both JECFA (2009a) and 39 
EFSA (2010k). Because a comprehensive and adequate toxicological database is available for steviol 40 
glycosides the candidate substance rebaudioside A [FL-no: 16.113] should not be evaluated using the 41 
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Procedure as referred to in the Commission Regulation EC No 1565/2000 (EC, 2000a). The flavouring 1 
substance under consideration, as well as its chemical Register name, FLAVIS- (FL-), Chemical 2 
Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufacturers 3 
Association- (FEMA-) number, structure and specifications, are listed in Table 1.  4 
The flavouring substance rebaudioside A (13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-5 
D-glucopyranosyl) oxy]kaur-16-en-8-oic acid, β-D-glucopyranosyl ester) [FL-no: 16.113] (candidate 6 
substance) is closely related structurally to stevioside (13-[(2-O-β-D-glucopyranosyl-β-D-7 
glucopyranosyl) oxy]kaur-16-en-18-oic acid, β-D-glucopyranosyl ester). Both compounds contain the 8 
same aglycon steviol, the only difference being that rebaudioside A contains an extra glucose 9 
molecule in the glycoside moiety.  10 
 11 
Steviol glycosides are chemically defined mixtures that comprise not less than 95 % stevioside and/or 12 
rebaudioside A. Smaller amounts of rebaudiosides B, C, D, E and F, steviolbioside, rubusoside and 13 
dulcoside A are present in the final mixtures. In one product evaluated as a sweetener, rebaudioside A 14 
is the major component of the mixture (≥ 95%). 15 
 16 
The outcome of the Safety Evaluation is summarised in Table 2a. 17 
The hydrolysis products of rebaudioside A are shown in Table 2b and the closely related substances, 18 
stevioside and steviol (supporting substances), are listed in Table 3. 19 
1.2. Stereoisomers 20 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 21 
flavour may be different, they may have different chemical properties resulting in possible variability 22 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 23 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 24 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 25 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 26 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 27 
substances with different configurations should have individual chemical names and codes (CAS 28 
number, FLAVIS number etc.). 29 
The candidate substance possesses several chiral centres. The geometrical stereoisomer is as 30 
designated in the structural formula (See Table 1). 31 
1.3. Natural Occurrence in Food 32 
According to the Industry, rebaudioside A [FL-no: 16.113] has been found in Stevia rebaudiana, up to 33 
16200 – 72700 mg/kg, depending on plant species (Flavour Industry, 2009q). 34 
1.4. Evaluations From Other Expert Groups 35 
Rebaudioside A [FL-no: 16.113] (together with stevioside) was latest evaluated as a sweetener by the 36 
JECFA in 2008 (JECFA 2009a) and by EFSA in 2010 (EFSA 2010k). Both established an Acceptable 37 
Daily Intake (ADI) for steviol glycosides, expressed as steviol, of 0-4 mg/kg body weight (bw)/day. 38 
At its meeting in 1998 (JECFA, 1999a) the JECFA requested further toxicological data on stevioside 39 
and the aglycone steviol. In 2004, based on new data, the JECFA established  a temporary ADI of 0–2 40 
mg/kg bw for steviol glycosides, expressed as steviol, on the basis of the NOEL for stevioside of 970 41 
mg/kg bw per day (or 383 mg/kg bw per day expressed as steviol) in a 2-year study in rats and a safety 42 
factor of 200 (JECFA, 2006a). The ADI was made temporary and the additional safety factor applied 43 
was due to lack of data on pharmacological effects of steviol glycosides in humans. The JECFA noted 44 
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that stevioside was being investigated as a potential treatment for hypertension and diabetes, with 1 
some evidence of pharmacological effects at higher doses. There was inadequate data to assess 2 
whether these pharmacological effects would also occur at lower levels of dietary exposure, which 3 
could lead to adverse effects in some individuals. Therefore, the JECFA requested additional human 4 
studies to address effects in diabetics, as well as normotensive and hypotensive individuals. It was 5 
reconsidered again at the JECFA meeting in 2007 at which meeting the temporary ADI of 0 - 2 mg 6 
steviol glycosides/kg bw was confirmed (JECFA, 2008b). In 2008, the JECFA removed the temporary 7 
designation and established an ADI for steviol glycosides of 0 - 4 mg/kg bw expressed as steviol based 8 
on new studies, showing no adverse effects of steviol glycosides when taken at doses of about 4 mg/kg 9 
bw per day (as steviol), for up to 16 weeks by individuals with type 2 diabetes mellitus and individuals 10 
with normal or low-normal blood pressure for 4 weeks. Steviol glycosides are a mixture of compounds 11 
with different molecular weights. Since the actual active ingredient is the steviol part of the different 12 
molecules, the 0 - 4 mg refers only to the molecular weight of total steviol in the mixture. The JECFA 13 
further stated in its evaluation that “The Committee noted that some estimates of high-percentile 14 
dietary exposure to steviol glycosides exceeded the ADI, particularly when assuming complete 15 
replacement of caloric sweeteners with steviol glycosides, but recognized that these estimates were 16 
highly conservative and that actual intakes were likely to be within the ADI range.” (JECFA, 2009a). 17 
The SCF latest evaluated stevioside as a potential sweetener in 1999 (SCF, 1999). The SCF considered 18 
the data available at the time of the evaluation to be insufficient to adequately assess the safety of 19 
stevioside and concluded that the use of stevioside was “toxicologically not acceptable”. Several 20 
concerns were raised by the SCF regarding the specifications of the extracts that had been tested (for 21 
the majority of toxicological studies a precise composition of the extract was not adequately defined), 22 
metabolism, chronic toxicity and carcinogenicity studies, possible effects on the male reproductive 23 
system, on renal and cardiovascular function and on carbohydrate metabolism. Furthermore, steviol, 24 
the main metabolite of stevioside, was found to be genotoxic and to induce developmental toxicity 25 
(SCF, 1999). 26 
However, EFSA has recently, following a request from the European Commission and based on a 27 
number of new studies, published a scientific Opinion on the safety of steviol glycosides (including 28 
rebaudioside A) as a sweetener for use in food (EFSA, 2010k). The new studies removed the concerns 29 
expressed by the SCF (1999) and EFSA established an ADI for steviol glycosides of well-30 
characterised composition, expressed as steviol equivalents, of 4 mg/kg bw/day based on a 2-year 31 
carcinogenicity study in the rat given 2.5 % stevioside in the diet. This is equal to 967 mg/kg bw/day. 32 
In the present scientific Opinion, the evaluation of rebaudioside A [FL-no: 16.113] as a flavouring 33 
substance, is based on the data in the EFSA Opinion on the use of steviol glycosides as a food additive 34 
(sweetener) (EFSA, 2010k) and on the review by Roberts & Renwick (2008). 35 
2. Specifications 36 
Purity criteria for the substance have been provided by the Flavour Industry (Flavour Industry, 2009q) 37 
(Table 1). 38 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 39 
2000a), this information is adequate for the candidate substance (See Section 1.2 and Table 1). 40 
3. Intake Data 41 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 42 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 43 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 44 
population are consumers (SCF, 1999a). 45 
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However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 1 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 2 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 3 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 4 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 5 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 6 
such cases, the human exposure thresholds below which exposures are not considered to present a 7 
safety concern might be exceeded. 8 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 9 
groups of consumers, the SCF recommended also taking into account the results of other intake 10 
assessments (SCF, 1999a). 11 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 12 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 13 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 14 
as a conservative estimate of the actual intake by most consumers because it is based on the 15 
assumption that the consumer regularly eats and drinks several food products containing the same 16 
flavouring substance at the upper use level. 17 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 18 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 19 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 20 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 21 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 22 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 23 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 24 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 25 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 26 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 27 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 28 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 29 
in food. 30 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 31 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 32 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 33 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 34 
The total annual volume of production of the candidate substance in the present Flavouring Group 35 
Evaluation (FGE.310) from (the anticipated) use as flavouring substance in Europe has been reported 36 
to be approximately 10000 kg (Flavour Industry, 2009q). 37 
On the basis of the annual volume of production reported for the candidate substance, the daily per 38 
capita intake for the flavouring has been estimated. The estimated daily per capita intake of 39 
rebaudioside A from use as a flavouring substance is 1200 microgram (Table 2a). 40 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 1 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 2 
is based on the approach used by SCF up to 1995 (SCF, 1995). 3 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 4 
day. 5 
For the candidate substance information on food categories and normal and maximum use levels5,6 6 
were submitted by the Flavour Industry (Flavour Industry, 2009q). The candidate substance is used in 7 
flavoured food products divided into the food categories, outlined in Annex III of the Commission 8 
Regulation (EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the present calculation of 9 
mTAMDI, the reported normal use levels were used. In the case where different use levels were 10 
reported for different food categories the highest reported normal use level was used. 11 
Table 3.1 Use of Candidate Substance* 
Food 
category 
Description Flavouring used 
01.0 Dairy products, excluding products of category 2 Yes 
02.0 Fats and oils, and fat emulsions (type water-in-oil) No 
03.0 Edible ices, including sherbet and sorbet Yes 
04.1 Processed fruits Yes 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
No 
05.0 Confectionery Yes 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
Yes 
07.0 Bakery wares No 
08.0 Meat and meat products, including poultry and game No 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  No 
10.0 Eggs and egg products No 
11.0 Sweeteners, including honey No 
12.0 Salts, spices, soups, sauces, salads, protein products etc. Yes 
13.0 Foodstuffs intended for particular nutritional uses No 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products Yes 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts Yes 
15.0 Ready-to-eat savouries No 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
No 
*The flavouring substance is also anticipated to be used in chewing gum, which is not included in any of the categories in  12 
the above table.  13 
 14 
According to the Flavour Industry the normal use levels for the candidate substance are 20 mg/kg food 15 
and the maximum use levels are 30 mg/kg (Flavour Industry, 2009q). 16 
The mTAMDI value is 10,888 microgram/person/day for the candidate substance from structural class 17 
III (see Section 5).  18 
The use levels as a sweetener range from 110 to 10,000 mg/kg food (EFSA, 2010k). 19 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
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For detailed information on use levels and intake estimations based on the mTAMDI approach, see 1 
Section 6 and Annex II. 2 
4. Absorption, Distribution, Metabolism and Elimination 3 
In 2008 Roberts & Renwick reviewed the available literature on the role of the gut microflora in the 4 
metabolism of steviol glycosides, stevioside and rebaudioside A to establish that the safety data on 5 
stevioside can be extrapolated to the structurally related glycoside rebaudioside A (Roberts & 6 
Renwick, 2008). Roberts & Renwick (2008) considered that: 7 
 8 
• Both stevioside and rebaudioside A undergo hydrolysis by mixed intestinal flora to steviol and the 9 
rate of hydrolysis of stevioside is slightly greater than that of rebaudioside A. 10 
• Hydrolysis proceeds via initial formation of steviolbioside with steviol as the final product of 11 
hydrolysis. 12 
• Steviol is not metabolized by the intestinal flora and is absorbed from the intestine.  13 
• Steviol-16,17-epoxide was not detected as a microbial metabolite of steviol glycosides. 14 
• Fecal incubation studies with both human and animal mixed flora provide similar results and hence 15 
the rat represents a suitable model for human metabolism of stevioside and rebaudioside A.  16 
Based on these findings Roberts & Renwick (2008) concluded that the data on the toxicological 17 
effects of stevioside can be extrapolated to rebaudioside A because of the overall similarities in the 18 
metabolic fates of stevioside and rebaudioside A on incubation with the intestinal microflora with 19 
essentially quantitative formation of steviol, the comparable rates of hydrolysis, and the negligible 20 
changes in flora produced by prolonged incubation with these glycosides.  21 
In 2010 the EFSA ANS Panel in its Opinion on steviol glycosides considered that: “Metabolic studies 22 
with steviol glycosides in animals and humans demonstrated that intact steviol glycosides are poorly 23 
absorbed after oral exposure but that they are hydrolysed by the microflora in the colon to steviol. A 24 
large amount of steviol is absorbed; the rest is excreted in the faeces. In the liver, steviol undergoes 25 
conjugation with glucuronic acid to form steviol glucuronide. The only interspecies difference is that 26 
the glucuronide is excreted primarily via the urine in humans and via the bile in rats. No accumulation 27 
of steviol glycoside derivatives occurs in the body. Besides steviol glucuronide, no other derivatives 28 
could be detected in the urine of humans exposed orally to steviol glycosides. Rebaudioside A and 29 
stevioside both show similar pharmacokinetics in the rat. In humans, rebaudioside A and stevioside are 30 
also metabolised and excreted by similar pathways. Therefore, the ANS Panel considered the results of 31 
toxicological studies on either stevioside or rebaudioside A applicable for the safety assessment of 32 
steviol glycosides in general.“ 33 
The CEF Panel concurs with the conclusions, that rebaudioside A and stevioside both show similar 34 
pharmacokinetics in the rat and humans, that they are both metabolised to the same active metabolite 35 
steviol, and the results of toxicological studies on either stevioside or rebaudioside A are applicable for 36 
the safety assessment of steviol glycosides in general. 37 
For more detailed information on absorption, distribution, metabolism and excretion, see Annex III. 38 
5. Safety Evaluation of the Flavouring Substance 39 
The application of the Procedure as referred to in the Commission Regulation EC No 1565/2000 (EC, 40 
2000a) is based on intakes estimated on the basis of the MSDI approach. Where the mTAMDI 41 
approach indicates that the intake of a flavouring substance might exceed its corresponding threshold 42 
of concern, a formal safety assessment is not carried out using the Procedure. In these cases the Panel 43 
requires more precise data on use and use levels. For comparison of the intake estimations based on 44 
the MSDI approach and the mTAMDI approach, see Section 6. 45 
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For the safety evaluation of the candidate substance rebaudioside A [FL-no: 16.113] from chemical 1 
group 30 the Panel decided that the Procedure should not be applied. Instead the Panel based its 2 
evaluation on a comparison of the ADI of 4 mg/kg bw for steviol glycosides, expressed as steviol, 3 
established by EFSA (EFSA, 2010k) with the estimated MSDI (and mTAMDI). The ADI includes 4 
rebaudioside A which is also converted to steviol following ingestion. 5 
The MSDI of 1200 microgram rebaudioside A/capita/day, equivalent to 20 microgram rebaudioside 6 
A/kg bw/day, for a person weighing 60 kg, corresponds to a daily intake of 6.6 microgram steviol/kg 7 
bw/day, using a conversion factor of 0.33 (EFSA, 2010k) for converting the amount of rebaudioside A 8 
into steviol equivalents. This intake as a flavouring substance amounts to 0.17 % of the ADI of 4 9 
mg/kg bw, expressed as steviol, established by EFSA (2010k). 10 
The Panel concluded that rebaudioside A [FL-no: 16.113] does not pose a safety concern when used as 11 
flavouring substance at the estimated level of intake, based on the MSDI approach. 12 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 13 
Approach 14 
The estimated intake of the candidate substance rebaudioside A [FL-no: 16.113] based on the 15 
mTAMDI is 11088 microgram/person/day, which is equivalent to 181 microgram rebaudioside A/kg 16 
bw/day, for a person weighing 60 kg. This correspond to a daily intake of 60 microgram steviol/kg 17 
bw/day, using a conversion factor of 0.33 (EFSA, 2010k) for converting the amount of rebaudioside A 18 
into steviol equivalents. This intake as a flavouring substance amounts to 1.5 % of the ADI of 4 mg/kg 19 
bw, expressed as steviol, established by EFSA (2010k). 20 
The Panel concluded that rebaudioside A [FL-no: 16.113] does not pose a safety concern when used as 21 
flavouring substance at the estimated level of intake, based on the mTAMDI approach. 22 
For comparison of the MSDI and mTAMDI values, see Table 6.1 23 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
ADI (µg/person/day) 
16.113 Rebaudioside A 1200 11088 Class III 240000 
 24 
The intake as a flavouring substance amounting to 1.5 % of the ADI of 4 mg/kg bw, is far lower than 25 
the estimated intake as a sweetener. When considering the proposed maximum use levels for 26 
rebaudioside A as a sweetener, the mean dietary exposure to steviol glycosides expressed as steviol 27 
equivalents in European children and adults might in some cases exceed the ADI of 4 mg/kg bw/day 28 
(EFSA, 2011l). 29 
7. Considerations of Combined Intakes from Use as Flavouring Substances 30 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 31 
many of the flavourings are metabolised through the same metabolic pathways and that the 32 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 33 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 34 
considered. As flavourings not included in this FGE may also be metabolised through the same 35 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 36 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 37 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 38 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 39 
summing the MSDI for individual substances.  40 
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On the basis of the reported annual production volumes in Europe (Flavour Industry, 2009q), the 1 
estimated daily per capita intake as flavourings of the candidate substance belonging to structural 2 
class III is 1200 microgram (No structurally related flavourings). 3 
Steviol glycosides may also be authorised as food additives in the EU. In its recent revised exposure 4 
assessment the EFSA ANS Panel estimated the potential exposure to steviol glycosides from use as 5 
food additives (EFSA, 2011l). When considering the proposed maximum use levels (Tier 2), the mean 6 
dietary exposure to steviol glycosides expressed as steviol equivalents in European children (aged 1 - 7 
14 years) ranged from 0.4 to 6.4 mg/kg bw/day, and from 1.0 to 12.7 mg/kg bw/day at the 95th 8 
percentile. The main contributors (> 10 % in all countries) to the total anticipated exposure to steviol 9 
glycosides, expressed as steviol equivalents, are soft drinks (11 to 58 %) and desserts, including 10 
flavoured milk products (14 to 71%). Confectionery accounted for 11 % of exposure in two countries. 11 
Dried potato granules and flakes and candied fruits and vegetables, mostardo di frutta accounted for 17 12 
and 18% of exposure in one country. 13 
8. Toxicity 14 
Rebaudioside A and stevioside both show similar pharmacokinetics in the rat. In humans, rebaudioside 15 
A and stevioside are also metabolised and excreted by similar pathways. Therefore, the results of 16 
toxicological studies on either stevioside or rebaudioside A are applicable for the safety assessment of 17 
rebaudioside A. 18 
All the available toxicological studies on stevioside and rebaudioside A were recently evaluated by the 19 
EFSA ANS Panel (EFSA, 2010k). 20 
8.1. Acute Toxicity 21 
Acute oral toxicity studies with stevioside (purity 96 %) indicated an LD50 of more than 15 g/kg body 22 
weight (bw) in the mouse, rat and hamster (EFSA, 2010k). 23 
More information can be found in EFSA (2010k). 24 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 25 
The subacute, subchronic, chronic and carcinogenicity studies on stevioside and rebaudioside A were 26 
recently evaluated by the EFSA ANS Panel (EFSA, 2010k): 27 
In some of the subchronic and the 2-generation reproductive toxicity studies in rats with rebaudioside 28 
A, body weight gains were slightly lower in the treated groups compared to the controls. In these 29 
studies, decreases in feed consumption and in feed conversion efficiency were also recorded. The ANS 30 
Panel considered the effects on body weight as not adverse or indicative of toxicity but related to 31 
lower palatability and lower nutritional value of feed containing the test steviol glycosides (97 % 32 
rebaudioside A). Therefore the body weight parameters are not considered appropriate endpoints for 33 
setting NOAELs for these studies”. Accordingly, the ANS Panel considered that steviol glycosides 34 
administered in the diet to rats did not produce adverse effects in subchronic studies at doses up to 4.6 35 
g/kg bw/day. The NOAELs in these studies were the maximum doses tested. 36 
“No new chronic toxicity or carcinogenicity studies with steviol glycosides since the evaluation of 37 
stevioside by the SCF in 1999 were provided by the petitioners. The available long-term 38 
toxicity/carcinogenicity studies showed no indication of toxicity associated with prolonged high-dose 39 
dietary exposure to steviol glycosides or evidence of carcinogenic potential. The NOAEL in the 2-year 40 
carcinogenicity rat study conducted with stevioside (95.6 % purity) was 2.5 % stevioside in the diet, 41 
equal to 967 and 1120 mg/kg bw/day in males and females, respectively (corresponding to 42 
approximately 388 mg steviol equivalents/kg bw/day). Since negative carcinogenicity data were 43 
consistently observed in three studies in the rat and steviol glycosides do not exert tumour promoting 44 
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activity in various experimental models the Panel considers that there is no need to further test the 1 
potential carcinogenicity of steviol glycosides in other species (i.e. mouse). 2 
More detailed information can be found in EFSA (2010k). 3 
Other studies 4 
In its evaluation of stevioside as a sweetener, the SCF (1999) expressed a concern regarding the 5 
potential effects of steviol glycosides on the renal and cardiovascular function and on carbohydrate 6 
metabolism. Several in vitro studies had shown that steviol glycosides interfered with the transport of 7 
anions in the renal tubules, inhibited vasoconstriction, and stimulated insulin secretion from isolated 8 
pancreatic islet cells. Most of these studies did not provide data that can be extrapolated to the in vivo 9 
situation. However, in vivo studies in normal, diabetic or obese rats also indicated that steviol 10 
glycosides may impact blood glucose homeostasis parameters and lower blood pressure. An in vivo 11 
study of potential effects on renal function from Stevia extract and stevioside administered orally, 12 
demonstrated that both compounds were well-tolerated and displayed no treatment-related effects on 13 
kidney function in dogs. 14 
More detailed information can be found in EFSA (2010k). 15 
8.3. Developmental / Reproductive Toxicity Studies 16 
The developmental/reproductive toxicity studies on stevioside and rebaudioside A were recently 17 
evaluated by the EFSA ANS Panel (EFSA, 2010k): 18 
Earlier concerns by the SCF (SCF, 1999b) about potential adverse effects on the male reproductive 19 
system raised by the findings in a chronic toxicity study in F344 rats with Stevia extract (74.54% 20 
stevioside and 16.27 % rebaudioside A) were considered by the Panel to have been adequately 21 
clarified by the results of later reproductive toxicity studies with test materials of known composition 22 
and high purity. The testicular changes reported in the chronic toxicity study were unlikely to have 23 
been caused by steviol glycosides. The ANS Panel noted that in the past, aqueous Stevia rebaudiana 24 
extracts administered orally to female mice and rats at doses up to 2000 mg/kg bw/day were reported 25 
to have contraceptive effects and that adverse male reproductive effects were observed in rats 26 
following administration of Stevia rebaudiana leaf extracts. Since publication of these studies, several 27 
reproductive (multigenerational studies) and developmental (teratology) studies were conducted with 28 
stevioside and steviol glycosides and the studies with steviol glycosides complying with the JECFA 29 
specifications did not affect reproduction or the developing fetus. Administration of stevioside (purity 30 
90 - 96 %) at doses up to 2500 mg/kg bw/day to hamsters and 2100 mg/kg bw/day (3 % in the diet) to 31 
rats had no adverse effects on fertility and the development of fetuses. The 2-generation study in rats 32 
with the steviol glycosides (97 % rebaudioside A) did not reveal any adverse effects at the highest 33 
dietary dose tested of 25 000 mg/kg diet, corresponding to 2048 - 2273 mg/kg bw/day. Steviol 34 
glycosides (97 % rebaudioside A) in doses up to 1400 mg/kg bw/day had no adverse effects on 35 
developing fetuses in NZW rabbits (Charles River Laboratories, 2008). Overall, it was concluded that 36 
steviol glycosides complying with JECFA specifications administered orally are unlikely to have 37 
adverse reproductive and developmental effects. 38 
Steviol, the metabolite of all the steviol glycosides has been shown to induce maternal and 39 
developmental toxicity at high doses. The ANS Panel noted that any studies conducted on steviol at 40 
high doses are of little relevance to the safety assessment of the steviol glycoside preparations used as 41 
food additives. This is because steviol is absorbed immediately in the gastrointestinal tract following 42 
oral administration, but steviol glycosides are not readily absorbed in the gastrointestinal tract and are 43 
slowly hydrolysed to the aglycone steviol. The plasma levels of steviol after administration of a high-44 
dose of steviol, therefore, would be expected to be much greater than the plasma levels of steviol 45 
following administration of a steviol glycoside. 46 
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More detailed information can be found in EFSA (2010k). 1 
8.4. Genotoxicity Studies 2 
The gentoxicity studies on stevioside and rebaudioside A were recently evaluated by the EFSA ANS 3 
Panel (EFSA, 2010k): 4 
Overall, stevioside and rebaudioside A do not show evidence of genotoxicity in vitro or in vivo. 5 
Although a single Comet assay was reported to show effects indicative of DNA damage, the Panel 6 
considers that this study does not provide substantive evidence of a genotoxic potential for stevioside, 7 
given methodological concerns and also the fact that similar findings were not seen in earlier studies in 8 
mice using steviol glycosides of higher or lower purities. The Panel notes that steviol and some of its 9 
oxidative derivates show clear evidence of genotoxicity in vitro, particularly in the presence of a 10 
metabolic activation system. However, studies of DNA damage and micronucleus formation in rats, 11 
mice and hamsters have shown that the genotoxicity of steviol is not expressed in vivo at doses of up 12 
to 8000 mg/kg bw. Given that the available toxicokinetic data indicate that free steviol is absent from 13 
the systemic circulation in humans or, at worst, present at very low (negligible) levels, any concern 14 
raised by the in vitro genotoxicity profile of steviol is fully addressed by the fact that the genotoxic 15 
potential of steviol is not expressed in vivo, and by the negative genotoxicity findings for steviol 16 
glycosides in vitro and in vivo.  17 
9. Human Studies 18 
The available studies in humans on stevioside and rebaudioside A were recently evaluated by the 19 
EFSA ANS Panel (EFSA, 2010k): 20 
Single doses of 1000 mg steviol glycosides/person/day (97 % rebaudioside A) (corresponding to 21 
approximately 330 mg steviol equivalents/day) did not affect glucose homeostasis and did not affect 22 
blood pressure in individuals with normal glucose tolerance or type-2 diabetes mellitus. Also repeated 23 
use for 16 weeks of 1000 mg rebaudioside A/person/day did not alter glucose homeostasis in 24 
individuals with type-2 diabetes mellitus. Blood pressure parameters were not significantly affected by 25 
oral intake of 1000 mg rebaudioside A/person/day for 4 weeks in individuals with normal and low 26 
systolic blood pressure. This daily dose corresponds to 16.6 mg of rebaudioside A/kg bw for a person 27 
weighing 60 kg and to approximately 5.5 mg steviol equivalents/kg bw/day. Thus, no adverse effects 28 
of steviol glycosides were observed when taken at doses of about the ADI of 4 mg/kg bw per day (as 29 
steviol), by individuals with type 2 diabetes mellitus and individuals with normal or low-normal blood 30 
pressure. 31 
10. Conclusions 32 
The present Flavouring Group Evaluation deals with one newly notified substance, the steviol 33 
glycoside rebaudioside A [FL-no: 16.113] from chemical group 30, Annex I of Commission 34 
Regulation (EC) No 1565/2000 (EC, 2000a).  35 
It has been reported that the flavouring substance occurs naturally in Stevia rebaudiana, up to 16200 – 36 
72700 mg/kg, depending on plant species. 37 
The flavouring substance is included in the specifications for the food additive (sweetener) steviol 38 
glycosides which has recently been evaluated by both the JECFA (JECFA, 2009a) and EFSA (EFSA, 39 
2010k). The flavouring substance rebaudioside A [FL-no: 16.113] is closely related structurally to 40 
stevioside. Both compounds contain the same aglycon steviol, the only difference being that 41 
rebaudioside A contains an extra glucose molecule in the glycoside moiety. Steviol glycosides are 42 
chemically defined mixtures that comprise not less than 95 % stevioside and/or rebaudioside A. Both 43 
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the JECFA and EFSA established an ADI for steviol glycosides (including rebaudioside A), expressed 1 
as steviol equivalents, of 4 mg/kg bw/day. 2 
Overall, stevioside and rebaudioside A do not show evidence of genotoxicity in vitro or in vivo. 3 
Because a comprehensive and adequate toxicological database, including human studies, is available 4 
for steviol glycosides the candidate substance rebaudioside A [FL-no: 16.113] should not be evaluated 5 
using the Procedure as referred to in the Commission Regulation EC No 1565/2000 (EC, 2000a). 6 
Instead the Panel based its evaluation on a comparison of the ADI of 4 mg/kg bw, expressed as steviol, 7 
established by EFSA (EFSA, 2010k) with the estimated MSDI and mTAMDI values. 8 
According to the default MSDI approach, the substance has a daily per capita intake as a flavouring of 9 
1200 microgram/capita/day. The MSDI of 1200 microgram rebaudioside A/capita/day, equivalent to 10 
20 microgram rebaudioside A/kg bw/day, for a person weighing 60 kg, corresponding to a daily intake 11 
of 6.6 microgram steviol/kg bw/day, using a conversion factor of 0.33 (EFSA, 2010k) for converting 12 
the amount of rebaudioside A into steviol equivalents. This intake, as a flavouring substance, amounts 13 
to 0.17 % of the ADI of 4 mg/kg bw, expressed as steviol, established by EFSA (EFSA, 2010k). The 14 
Panel concluded that rebaudioside A [FL-no: 16.113] does not pose a safety concern when used as 15 
flavouring substance at the estimated level of intake, based on the MSDI approach. 16 
The estimated intake of the candidate substance rebaudioside A [FL-no: 16.113] based on the 17 
mTAMDI is 10888 microgram/person/day, is equivalent to 181 microgram rebaudioside A/kg bw/day, 18 
for a person weighing 60 kg. This correspond to a daily intake of 60 microgram steviol/kg bw/day, 19 
using a conversion factor of 0.33 (EFSA, 2010k) for converting the amount of rebaudioside A into 20 
steviol equivalents. This intake amounts to 1.5 % of the ADI of 4 mg/kg bw, expressed as steviol, 21 
established by EFSA (EFSA, 2010k). The Panel concluded that rebaudioside A [FL-no: 16.113] does 22 
not pose a safety concern when used as flavouring substance at the estimated level of intake, based on 23 
the mTAMDI approach. 24 
Steviol glycosides are (expected to be) authorised as food additives in the EU. The Panel noted that in 25 
its recent evaluation the EFSA ANS Panel estimated the potential exposure to steviol glycosides from 26 
use as food additives. When considering the proposed maximum use levels as food additive, the mean 27 
dietary exposure to steviol glycosides expressed as steviol equivalents in European children might 28 
exceed the ADI of 4 mg/kg bw/day. Thus, the estimated intake of rebaudioside A [FL-no: 16.113] 29 
from its use as a flavouring substance contributes to the total intake of steviol glycosides. 30 
In order to determine whether the conclusion for the flavouring substance can be applied to the 31 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 32 
including complete purity criteria and identity for the materials of commerce have been provided for 33 
the flavouring substance rebaudioside A [FL-no: 16.113]. 34 
The Panel concluded that on the basis of the default MSDI approach and the mTAMDI approach, 35 
rebaudioside A [FL-no: 16.113] would not give rise to safety concerns at the estimated level of 36 
intake arising from its use as flavouring substance.    37 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 310 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 310 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
16.113 
INS960 
Rebaudioside A 
O
HO
OH
H
OH
HO
O
O
O
H
HO
O
O
O
O
H
HO
OH
H
H
HO OH
HO
OH
HO
HO
O
OH
S
S
S
S
S
S
S
S
S
S
S
S
S
S
R
R
R
RRR
R
R
R
R
R
R
4601 
 
58543-16-1 
Solid 
C44 H70 O23 
967.01 
Very soluble 
Very soluble 
 
210-215 
NMR MS 
99 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
16.113 
 
Rebaudioside A 
O
HO
OH
H
OH
HO
O
O
O
H
HO
O
O
O
O
H
HO
OH
H
H
HO OH
HO
OH
HO
HO
O
OH
S
S
S
S
S
S
S
S
S
S
S
S
S
S
R
R
R
RRR
R
R
R
R
R
R
1200 
 
Class III 
No evaluation via the 
Procedure 
4 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no Name 
 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
- Steviol OH
HO
H
H
O
S
S
S
R
R
R
Evaluated as a sweetener  
Evaluated as a sweetener 
- 
Evaluated as a sweetener (ADI of 4 mg/kg 
bw) as steviol (EFSA, 2010k) 
 ADI of 0-4 mg/kg bw as steviol (JECFA, 
2009a) 
Not in Register 
- Glucose 
OH
O
HO OH
HO
OH - - Not in Register 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name/ 
Name of structurally related 
substance 
Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
- Stevioside 
OH
O
O
H
HO
O
O
O
O
H
HO
OH
H
H
HO OH
HO
OH
HO
HO
O
OH
S
S
S
S
S
S
S
S
S
S
S
R
RRR
R
R
R
R
R
R
57817-89-7    Not in Register. 
Evaluated as a 
sweetener (ADI of 4 
mg/kg bw) as steviol 
(EFSA, 2010k). 
- Steviol OH
HO
H
H
O
S
S
S
R
R
R
471-80-7  Not in Register. 
Evaluated as a 
sweetener (ADI 4 
mg/kg). 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products7 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous8 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
7 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
8 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 1 
II.1 Normal and Maximum Use Levels 2 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 3 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 4 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 5 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 6 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 7 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 8 
The “normal and maximum use levels” are provided by Industry for the candidate substance in the present 9 
flavouring group (Table II.1.2). 10 
 11 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substance in FGE.310 (Flavour 
Industry, 2009q). 
FL-no Food Categories (a) 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.113 20 
30 
- 
- 
20 
30 
20 
30 
- 
- 
20 
30 
20 
30 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
20 
30 
- 
- 
20 
30 
20 
30 
- 
- 
- 
- 
(a)   The candidate substance [FL-no. 16.113] is also anticipated to be used in chewing gum, which is not covered by any of the food 12 
categories. Normal/maximum use levels for chewing gum are reported to be 200 mg/kg for [FL-no: 16.113]. For chewing gum, 13 
the intake estimate is 2 g/day. It is anticipated that all of the flavouring substance is released from the chewing gum. In the 14 
calculation of the mTAMDI of the candidate substance, use level figures in Table II.1.2 and the use level of chewing gum (use 15 
level of chewing gum reported to be 200 mg/kg) x 2 (g daily intake of chewing gum)  =  mg/person/day) is summed up with the 16 
other food categories to a total mTAMDI value of 10888 µg/person/day presented in table II.2.3 and 6.1. 17 
 18 
II.2 mTAMDI Calculations 19 
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The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 1 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 2 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 3 
multiplied by the reported use levels in the different food categories and summed up.  4 
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 5 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 6 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 7 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 8 
following way (see Table II.2.2): 9 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 10 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 11 
(EC, 2000a) 12 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 13 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 14 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 15 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 16 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 17 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 1 
The mTAMDI values (see Table II.2.3) are presented for each of the candidate substance in the present 2 
flavouring group, for which Industry has provided use and use levels (Flavour Industry, 2009q). The 3 
mTAMDI values are only given for the highest reported normal use levels. 4 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name  mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
16.113 Rebaudioside A  10888 Class III 90 
 5 
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ANNEX III: ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION (ADME) 1 
In the following, the text on ADME from the EFSA ANS Panel evaluation of steviol glycosides 2 
(EFSA, 2010k) and additional information provided by the industry (Robers and Renwick 2008) is 3 
given in order to provide insight in the background for establishing an ADI covering both stevioside 4 
and rebaudioside A.  5 
EFSA ANS Panel evaluation: 6 
In vitro studies 7 
The metabolism of stevioside (purity not reported) was studied by using various digestive enzymes or 8 
fluids like salivary α-amylase, pancreatic α-amylase, saliva, pepsin, gastric secretion, pancreatin and 9 
intestinal brush border membrane enzymes of rodents as well as by the intestinal microflora of various 10 
species including humans (Hutapea et al., 1997). None of these enzymes digested stevioside. 11 
However, the caecal microflora of all species tested was able to metabolise stevioside to steviol. A 12 
transient formation of steviol-16,17 α-epoxide was observed in mouse caecal contents and human 13 
faeces. The authors suggested that steviol is the major metabolite produced by caecal microflora from 14 
various animal species and humans. Regarding human, intestinal metabolism of steviol glycosides, a 15 
study was undertaken by (Koyama et al., 2003a) to investigate human intestinal metabolism of a 16 
Stevia mixture (28.8 % rebaudioside A, 17 % stevioside, 25.2 % rebaudioside C, 10.2 % dulcoside) 17 
and its α-glucose derivative by LC-MS analysis. The Panel notes that the authors had also studied α-18 
glucose derivatives of the Stevia mixture, the precise composition of this is unclear from the published 19 
information and the Panel considers that these data are irrelevant to the steviol glycosides considered 20 
in this Opinion. Metabolism was examined by incubating the Stevia mixture, its α-glucose derivative, 21 
stevioside, rebaudioside A, α-monoglucosylstevioside, α-monoglucosylrebaudioside A and the 22 
aglycone steviol with pooled human faecal homogenates (obtained from five healthy volunteers, no 23 
age indicated) for 0, 8 and 24 hours under anaerobic conditions. The Stevia mixture, its α-glucose 24 
derivative, stevioside and rebaudioside A (0.2 mg/mL) were completely metabolised to steviol within 25 
24 hours, whereas no metabolism of steviol (0.08 and 0.2 mg/mL) appeared to be found during the 26 
incubation period. The Stevia mixture, stevioside and rebaudioside A appeared to be hydrolysed to 27 
steviol by human intestinal microflora. This observation is consistent with previous rat metabolism 28 
studies. Similarly, the α-glucose derivative appeared to be finally metabolised to steviol. Gardana et al. 29 
(2003) investigated the in vitro transformation of stevioside and rebaudioside A (Stevia extract 30 
containing either 85 % stevioside or 90 % rebaudioside A, respectively) after incubation with human 31 
intestinal microflora, the influence of these sweeteners on the human microbial faecal composition and 32 
which specific microbial species metabolise preferentially stevioside and rebaudioside A. The 33 
experiments were carried out under strict anaerobic conditions in batch cultures inoculated with mixed 34 
faecal bacteria from volunteers (6 males and 5 females aged between 20 and 50 years old). The 35 
hydrolysis was monitored by LC-MS analysis. Isolated bacterial strains from faecal materials 36 
incubated in selective broths were added to stevioside and rebaudioside A; these sweeteners were 37 
completely hydrolysed to their aglycone steviol within 10 and 24 hours, respectively. 38 
Interestingly, the human intestinal microflora was not able to degrade steviol. Furthermore, stevioside 39 
and rebaudioside A did not significantly influence the composition of faecal cultures. Among the 40 
selected species, bacteroides were the most efficient in converting steviol glycosides to steviol. The 41 
intestinal transport characteristics of stevioside, rebaudioside A (purity not reported) and steviol 42 
(purity not reported) were studied in Caco-2 cells (Geuns et al., 2003b). In comparison to steviol 43 
(apparent permeability value of 31.9 × 10−6 cm/s), only a minor fraction of stevioside and rebaudioside 44 
A was transported through the Caco-2 cell layer giving apparent permeability values of 0.16 × 10−6 45 
and 0.11 × 10−6 cm/s, respectively. In addition, the apparent permeability value for the absorptive 46 
transport of steviol was about 7 times higher than that for the secretory transport of steviol, suggesting 47 
a carrier mediated transport. The Panel notes that in this intestinal model, the apparent permeability 48 
value for steviol is 200 to 300 times higher than that for stevioside or rebaudioside A. 49 
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Regarding steviol hepatic metabolism, Compadre et al. (1988) demonstrated the very low conversion 1 
of steviol (purity not reported) into oxidative metabolites by microsomal fractions from Aroclor 1254-2 
pretreated rats. However, the authors noted the possible mutagenic activity of 15-oxosteviol, a 3 
metabolite which could be formed after a further oxidation of 15-hydroxysteviol. 4 
Koyama et al. (2003) incubated steviol (purity not reported) with rat (no pretreatment mentioned) or 5 
human (pooled from ten healthy donors, five male and five female) liver microsomes. In rats, 6 
monohydroxy- and dihydroxy-metabolites of steviol were observed by Liquid Chromatography 7 
Electrospray Ionisation Tandem Mass Spectrometry (LC-ESI-MS) after incubation with human liver 8 
microsomes. The intrinsic clearance of steviol in human liver microsomes was 4 times lower than that 9 
found in rat liver microsomes (Koyama et al., 2003b). However, this study suggested that there are no 10 
major species differences in steviol metabolites between rats and humans. The Panel notes that the 11 
authors concluded that extrapolation of toxicity data on steviol glycosides from rats to humans would 12 
therefore be valid. 13 
 14 
In vivo studies 15 
Animals 16 
By using intact ligated oral or bile duct cannulated rats, Wingard et al. (1980) demonstrated that 14C-17 
steviol (purity not reported) was almost totally absorbed from the rat lower bowel following 18 
intracaecal administration (Wingard et al., 1980). 19 
Uniformly labelled 3H-stevioside (95 % purity) prepared by gas tritiation was administered orally at a 20 
dose of 125 mg/kg bw to Wistar rats, and its disposition and metabolism were studied (Nakayama et 21 
al., 1986). The level of radioactivity in the blood increased slowly to a maximum of 4.83 microg 22 
stevioside equivalents/mL at 8 hours, exhibiting a biological half-life of 24 hours. At 1 hour, the 23 
highest concentration was observed in the small intestine, followed by the stomach and caecum in that 24 
order. At 4 hours, the concentration in the caecum was markedly higher than that in other tissues. 25 
Radioactivity remaining in the body at 45 hours was 30.7 % of the original dose. At 120 hours, the 26 
percentages of radioactivity excreted into the faeces and expired air were 68.4 % and 23.9 %, 27 
respectively, while radioactivity excreted into the urine was only 2.3 %. Radioactivity excreted into 28 
the bile at 72 hours was 40.9 % of the original dose. From the results of biliary and faecal excretion, it 29 
was concluded that enterohepatic circulation occurs in the body. TLC analysis of the intestinal 30 
contents, faeces and bile showed that stevioside is metabolised by caecal flora to steviol and sugars, 31 
and indicated that steviol and these sugars are absorbed from the caecum, distributed throughout the 32 
whole body, and excreted mainly into faeces and expired air.  33 
Koyama et al. investigated the absorption and the hepatic metabolism of both a Stevia mixture (main 34 
components: rebaudioside A, stevioside, rebaudioside C, dulcoside A) and steviol (purity not reported) 35 
in rats. Absorption was investigated both ex vivo and in vivo. In ex vivo experiments using the rat 36 
everted sac method, no absorption of the Stevia mixture was observed, but significant absorption of 37 
steviol was noted. In the in vivo experiment, rats received a single oral administration of either steviol 38 
or the Stevia mixture. A steviol peak concentration of 18 microg/mL in plasma was observed 15 39 
minutes after oral administration, demonstrating rapid absorption. However, after oral administration 40 
of the Stevia mixture, the steviol concentration in plasma increased steadily over 8 hours, suggesting 41 
that the Stevia mixture components are first metabolised and then absorbed as steviol in the rat 42 
intestine (Koyama et al., 2003b). 43 
Recently, the toxicokinetics and metabolism of rebaudioside A, stevioside and steviol (purity ≥ 97 %) 44 
were compared in rats to determine whether toxicological studies conducted previously with stevioside 45 
would be applicable to the structurally-related glycoside, rebaudioside A (Roberts & Renwick, 2008). 46 
Single oral doses of the 14C-compounds radiolabeled in the methylene group (=CH2) of the steviol 47 
moiety were extensively and rapidly absorbed with plasma concentration–time profiles following 48 
similar patterns for stevioside and rebaudioside A. Peak concentrations of radioactivity were at 49 
approximately 8 and 4 hours following doses of 14C-stevioside and 14C-rebaudioside A, respectively. 50 
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Elimination of radioactivity from plasma was essentially complete within 72 hours. All plasma 1 
samples had similar proportions of radioactive derivatives; the predominant radioactive component in 2 
all samples was steviol, with 5 to 17 times lower amounts of steviol glucuronide. One or two other 3 
unidentified metabolites were also present in plasma. Rebaudioside A, stevioside and steviol were 4 
metabolised and excreted rapidly, since 83 to 98 % of the radioactivity was eliminated in the faeces 5 
within 48 hours. Urinary excretion accounted for less than 2 % of the administered dose for all 6 
compounds in both intact and bile duct-cannulated rats, and 69 to 98 % of the absorbed dose was 7 
excreted via the bile. After administration of the compounds to intact and bile duct-cannulated rats, 8 
radioactivity in the faeces was present primarily as steviol. The predominant radioactive compound 9 
detected in the bile of all cannulated rats was steviol glucuronide, indicating de-conjugation of steviol 10 
glucoronide and rebaudioside A in the lower intestine. Overall, the data on toxicokinetics and 11 
metabolism indicate that stevioside and rebaudioside A are handled in a similar manner. The authors 12 
considered that these studies support the use of toxicological safety studies conducted with stevioside 13 
for the safety assessment of rebaudioside A. 14 
In pigs (6 females/group, body weight 26 kg) fed stevioside (purity ≥ 96 %) at a dose of 1.67 g/kg feed 15 
(equivalent to approximately 0.13 g stevioside/kg bw/day), stevioside was completely converted into 16 
steviol by the bacteria of the colon (Geuns et al., 2003a). However, no stevioside or steviol could be 17 
detected in the blood of the animals, by using a very sensitive fluorescent method of analysis 18 
(detection limits of 0.5 ng/mL and 0.5 pg/mL for stevioside and steviol respectively). The petitioner 19 
also indicated a study on broiler chickens administered either a single-dose or repeated doses of 20 
stevioside by gavage in which the glycoside was reported to be recovered largely unchanged within 21 
the excreta (Geuns et al., 2003b). 22 
Humans 23 
In a briefly described study, Kraemer and Maurer (1994) investigated the fate of stevioside (purity and 24 
dose not reported) in humans (gender and number not reported). After ingestion of stevioside, urine 25 
and faeces were collected over one week. The samples were analysed with or without enzymatic 26 
cleavage of conjugates after liquid-liquid extraction or solid phase extraction using HPLC and Gas 27 
chromatography-Mass Spectrometry (GC-MS). The structures of the metabolic products were 28 
determined using Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR) spectroscopy and 29 
chemical synthesis. Only small amounts of unchanged stevioside were excreted in faeces. Stevioside 30 
was readily metabolised to its aglycone steviol by human intestinal flora. The absorbed steviol was 31 
conjugated in the liver to an acyl-glucuronide which was excreted via bile and urine. Sixty percent of 32 
the applied amount of stevioside was recovered from urine as steviol glucuronide over a period of 33 
about 100 hours. This metabolite was also detected in the faeces during this period. Part of the 34 
glucuronide was metabolised by the intestinal flora to steviol, which can be reabsorbed and undergo 35 
an enterohepatic circulation. Further phase I or phase II metabolites were not found in urine or faeces 36 
(Kraemer and Maurer, 1994). 37 
Simonetti et al. (2004) investigated stevioside bioavailability and metabolic fate in human healthy 38 
volunteers (9 males aged between 25 and 50 years old) receiving 375 mg stevioside (from a Stevia 39 
extract containing 85 % stevioside) as a single oral dose. At the beginning and at different time-points 40 
after stevioside administration, plasma (0 - 5 hours post-dose), urine and faecal samples were 41 
collected, extracted and analysed for the presence of stevioside or its possible metabolites such us 42 
steviol, steviol-16,17-α-epoxide and 15-α-hydroxysteviol by means of a LC-MS method. In plasma, 43 
two peaks of steviol glucuronide occurred at 1-2 and 4 hours post-dose. The results obtained proved 44 
that stevioside is converted to steviol, which is subsequently absorbed and that steviol glucuronide is 45 
only found in plasma whilst steviol is only found in faeces. In addition, steviol-16,17-α-epoxide and 46 
15-α-hydroxy-steviol were not found in plasma, urine and faecal samples(Simonetti et al., 2004). In a 47 
further study by Geuns et al. stevioside (250 mg capsules; 97 % purity, impurities were 2.7 % 48 
steviolbioside and 0.3% rebaudioside A) was given thrice daily for 3 days to 10 healthy subjects (5 49 
females and 5 males aged between 21 and 29 years old) (Geuns et al., 2007). Blood samples were 50 
collected, before and at different time-points during the third day of stevioside administration. 51 
Stevioside, free steviol and steviol metabolites were analysed in blood, faeces and urine after 3 days of 52 
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stevioside administration. No uptake of stevioside was found by the gastrointestinal tract and the 1 
amounts taken up were below the detection limit of the analytical method (200 ng/mL). In plasma, no 2 
stevioside, no free steviol nor other free steviol metabolites were found. Steviol glucuronide was found 3 
at a maximum concentration of 33 microg/mL (21.3 microg steviol equivalents/mL). On the third day 4 
of the experiment, two plasma peaks occurred at 0.5 - 1 hour and 5 - 7 hours post-dose. In urine, no 5 
stevioside or free steviol were present, but steviol glucuronide was unambiguously identified (Geuns 6 
et al., 2006). Steviol glucuronide in human urine was found in amounts of up to 318 mg/24-hour urine 7 
(205 mg steviol equivalents/24 hours). No other steviol derivatives were detected. In faeces, besides 8 
free steviol, no other steviol metabolites or conjugates were detected. 9 
Recently, a double-blind, cross-over study assessed the comparative pharmacokinetics of steviol and 10 
steviol glucuronide following single oral doses of rebaudioside A (98.7 % purity) and stevioside (96.6 11 
% purity) in healthy adult male subjects (8 males aged between 18 and 45 years old) (Simonetti et al., 12 
2004). Steviol glucuronide appeared in the plasma of all subjects after administration of rebaudioside 13 
A or stevioside, with median plasma peak time values of 12 and 8 hours post-dose, respectively. In 14 
both cases, two plasma peaks occurred at 6-12 and 24 hours post-dose. Steviol glucuronide was 15 
eliminated from the plasma, with similar half-life values of approximately 14 hours for both 16 
compounds. No steviol epoxide, which may be mutagenic, was detected in plasma. Administration of 17 
rebaudioside A resulted in a significantly lower steviol glucuronide maximal plasma concentration 18 
(1472 ng/mL) than after administration of stevioside (1886 ng/mL). However, there was no significant 19 
difference between the geometric mean AUC0-t values found for steviol glucuronide after 20 
administration of rebaudioside A (30.8 ng hour/mL) or after administration of stevioside (34.1 ng 21 
hour/mL). Steviol glucuronide was excreted primarily in the urine of the subjects during the 72 hours 22 
collection period, accounting for 59% and 62% of the rebaudioside A and stevioside doses, 23 
respectively. No steviol glucuronide was detected in faeces (Simonetti et al., 2004). This 24 
pharmacokinetic analysis indicated that rebaudioside A and stevioside underwent similar metabolic 25 
and elimination pathways in humans with steviol glucuronide excreted primarily in the urine and 26 
steviol in the faeces. 27 
In summary, the Panel notes that in vitro studies demonstrated that human digestive enzymes are not 28 
capable of hydrolysing β-glycosidic bonds of steviol glycosides. However, the intestinal microflora of 29 
humans (and rats) is able to convert steviol glycosides to steviol. In addition, in the Caco-2 cell model 30 
the apparent permeability value of steviol was found to be 200 to 300-times higher than that of 31 
stevioside or rebaudioside A. Other in vitro studies assessing the metabolic transformation of steviol 32 
showed a similar formation of hydroxy-metabolites of steviol in the presence of rat or human liver 33 
microsomes. 34 
In vivo studies in rats receiving stevioside demonstrated that free steviol was the main metabolite 35 
present in plasma and it reached maximum plasma concentration 24 hours after administration. In 36 
animal liver, steviol was shown to primarily undergo conjugation with glucuronic acid to form steviol 37 
glucuronide, identified as the major metabolite in bile. From the results of biliary and faecal excretion, 38 
it can be concluded that in rats, enterohepatic circulation occurs. In rats, steviol has been shown to be 39 
primarily excreted in the faeces via the bile, and in smaller amounts in the urine. In human volunteers 40 
exposed orally to stevioside or rebaudioside A, no free steviol was detected in the blood but steviol 41 
glucuronide was found to be the main metabolite in plasma. No steviol epoxide, which may be 42 
mutagenic, was detected in human plasma. The presence of multiple peaks in time of plasma 43 
concentrations of steviol glucuronide indicates enterohepatic circulation of steviol in humans as 44 
experimentally demonstrated in rats. Steviol glucuronide was also reported to be the main metabolite 45 
found in the urine of subjects receiving stevioside or rebaudioside A; this elimination pathway 46 
accounted for about 60 % of the dose. Steviol was reported to be the main metabolite found in the 47 
faeces of humans receiving oral stevioside or rebaudioside A. The Panel considers that these 48 
toxicokinetic analyses indicated that rebaudioside A and stevioside underwent similar metabolic and 49 
elimination pathways in humans. Therefore, the Panel considers that the results of toxicology studies 50 
on either stevioside or rebaudioside A can be applicable for the safety evaluation of steviol glycosides 51 
in general. 52 
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The main metabolite in plasma is steviol glucuronide in humans and free steviol in rats; no steviol 1 
epoxide, which may be mutagenic, was detected in human plasma. Steviol glucuronide is excreted 2 
primarily via the urine in humans and via the bile in rats due to known species differences in the 3 
molecular weight threshold for biliary elimination. 4 
Additional studies on the ADME of steviol glycosides provided by industry: 5 
The metabolism of rebaudioside A, stevioside and steviol were examined in Sprague-Dawley rats in 6 
order to determine the toxicokinetic and metabolic similarities between stevioside and rebaudioside A 7 
(Roberts & Renwick, 2008). 8 
Animals 9 
Method: 10 
Test compounds were radiolabeled with 14C in the =CH2 group of the steviol moiety. For all studies 11 
the rats were given a single oral dose of rebaudioside A (5 mg/kg bw), stevioside (4.2 mg/kg bw) and 12 
steviol (1.6 mg/kg bw) in the pharmacokinetic, metabolism and excretion portions of the study. The 13 
pharmacokinetic study was conducted in 3 experiments. For experiment 1 groups of 3 male and 3 14 
female Sprague-Dawley rats were used and blood samples were taken from the tail vein of each animal 15 
at 0.5, 1, 4, 8, 12, and 24 hours after dosing. To obtain plasma metabolite profiles (experiment 2), four 16 
animals per sex per test compound were used. Blood samples were collected from two animals per sex 17 
at two different times after dosing by cardiac puncture under terminal anaesthesia. Blood was collected 18 
from the rats receiving 14C-rebaudioside A at 8 and 14hours after dosing. Blood was collected from the 19 
rats receiving 14C-stevioside at 4 and 8 hours after dosing for males and at 8 and 12 hours after dosing 20 
for females. Blood was collected from the rats receiving 14C-steviol at 0.5 and 8h after dosing. In the 21 
main study on plasma pharmacokinetics (experiment 3) 27 rats per sex per test compound received a 22 
single oral dose of the test substance and blood samples were collected from three animals per sex per 23 
compound by cardiac puncture under terminal anaesthesia at 0.25, 0.5, 1, 2, 4, 8, 24, 28 and 72 hours 24 
after dosing. For the metabolism and excretion study five intact rats per sex and five bile duct 25 
cannulated rats per sex received a single dose of each test substance. For each intact animal, urine was 26 
collected separately into solid CO2-cooled containers from 0 to 6 and 6 to 24 hours after dosing and at 27 
24-h intervals thereafter, up to 96 hours. Feces were collected from 0 to 24 h, 24 to 48, 48 to 72, and 28 
72 to 96 hours after dosing. For each cannulated rat, bile was collected at intervals of 0-3, 3-6, 6-9, 9-29 
12, 12-24 and 24 – 48 hours after dosing. At 96 and 48 hours after dosing, the intact and cannulated 30 
rats, respectively, were killed by cervical dislocation. The gastrointestinal tract (including contents) 31 
was removed from the carcasses of the intact rats and retained with the remaining carcasses. For the 32 
cannulated rats, the gastrointestinal tract (including contents) and the livers were removed from the 33 
carcasses and retained with the remaining carcasses.  34 
Results: 35 
Comparison of the pharmacokinetic parameters of total radioactivity following administration of 14C-36 
rebaudioside A, 14C-stevioside and 14C-steviol indicate that the pharmacokinetics of 14C-rebaudioside 37 
A, 14C-stevioside are similar, while the pharmacokinetics of 14C-steviol differ, especially in the rate of 38 
absorption. Qualitatively all plasma samples had similar metabolite profiles with steviol being the 39 
main radioactive component in the plasma. Lower amounts of steviol glucuronide and still lower 40 
amounts of one or two unidentified metabolites were also recorded. The observed pharmacokinetic 41 
parameters indicate that the peak plasma concentration (Cmax) and the Area Under Curve (AUC) for 42 
stevioside were similar but slightly higher than those of rebaudioside A. The plasma kinetic data 43 
indicate a sex difference in the Cmax and AUC for the total radioactivity, which was less apparent for 44 
steviol and was not reflected in the excretion data or the metabolism data (Table A). 45 
 46 
Table A: Pharmacokinetic parameters derived from mean total radioactivity concentrations in 47 
plasma following the administration of single oral doses of 14C-rebaudioside A, 14C-stevioside, 48 
and 14C-steviol (Roberts & Renwick, 2008). 49 
 50 
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Parameters for total 
radioactivity 
Administrated substance 
Rebaudioside A Stevioside Steviol 
Male Female Male Female Male Female 
Cmax (ng equiv./g) 90 177 101 279 114 264 
tMax (h) 2 8 4 8 0.25 264 
AUC72 (ng equiv. h/g) 645 3329 1617 4287 1251 1604 
AUCOC (ng equiv. h/g) 630 3349 1607a 4359 1926a 1926a 
K (hl) 0.1462 0.0821 0.0795a 0.0460 0.0437a 0.0427a 
T½ (h) 5 10 9a 15 16a 16 
aNot all of the criteria for reliability were met (see method section). 1 
Cmax - maximum observed plasma concentration. 2 
tMax - time of maximum observed plasma concentration. 3 
AUC72 - AUC calculated from 0-72 hours after administration. 4 
AUCOC - AUC extrapolated to infinity using the terminal slope. 5 
 6 
The absorption through the gut from rebaudioside A treatment was 71 % for males and 82 % for 7 
females. The corresponding absorption rates for stevioside was 97 % for males and 99 % for females 8 
and the one for steviol was 97 % for males and 99 % for females. Steviol was excreted predominantly 9 
in the feces where it was quantitatively the most significant radioactive component of intact rats dosed 10 
with 14C-rebaudioside A, 14C-stevioside and 14C-steviol. The parent glycoside and steviol glucuronide 11 
were identified as minor components as well. Steviol was also the principle radioactive component in 12 
the feces of bile duct-cannulated rats treated with 14C-rebaudioside A, 14C-stevioside. Steviol 13 
glucuronide was the predominant radioactive components in the bile of cannulated rats treated with 14 
14C-rebaudioside A, 14C-stevioside and 14C-steviol. The metabolite profile following administration of 15 
14C-rebaudioside A, 14C-stevioside and 14C-steviol is indicative of rapid first pass Phase II metabolism. 16 
Steviol glucuronides are subsequently eliminated in the bile and de-conjugated in the gastrointestinal 17 
tract prior to excretion in the feces. 18 
 19 
Conclusions: 20 
Steviol glycosides and steviol are extensively absorbed after oral dosing. Both, steviol glycoside and 21 
rebaudioside A are metabolised to steviol by the gut microflora prior to absorption. After absorption 22 
from the gut steviol is metabolized mainly to steviol glucuronide and excreted into the gastrointestinal 23 
tract via the bile. Due to the low levels of steviol glucuronide and high level of steviol in the feces of 24 
intact rats, it appears that the majority of steviol glucuronide is hydrolyzed back to steviol by the 25 
intestinal microflora. In rats rebaudioside A, stevioside and steviol are rapidly excreted as steviol, 26 
primarily in the feces with limited urinary elimination. The similarities in the kinetics and metabolism 27 
of rebaudioside A and stevioside support the use of previous toxicological studies conducted with 28 
stevioside for the human safety evaluation of rebaudioside A.  29 
 30 
 31 
Humans 32 
 33 
The comparative pharmacokinetics of steviol and steviol glucuronide following single oral doses of 34 
rebaudioside A and stevioside was studied in healthy adult males (Simonetti et al., 2004). 35 
 36 
Method: 37 
In a randomized, double-blind, cross-over study 8 healthy males received single oral doses of 5 mg/kg 38 
rebaudioside A and 4.2 mg/kg stevioside, equivalent to approximately 1.6 mg/kg of steviol 39 
equivalents. Plasma, urine and fecal samples where collected prior to dosing and up to 72 hours after 40 
dosing. 41 
 42 
Results: 43 
Steviol glucuronide appeared in the plasma of all subjects after administration of rebaudioside A or 44 
stevioside, with median tmax values of 12.0 and 8.00 hours post-dose, respectively. Steviol glucuronide 45 
was eliminated from the plasma, with similar t1/2 values of approximately 14 hours for both 46 
compounds. Administration of rebaudioside A resulted in a significantly (approximately 22 %) lower 47 
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steviol glucuronide geometric mean Cmax value (1472 ng/mg) than administration of stevioside (1886 1 
ng/ml). The geometric mean AUC0-t value for steviol glucuronide after administration of rebaudioside 2 
A (30,788 ng h/ml) was approximately 10 % lower than after administration of stevioside (34.090 ng 3 
h/ml) (Table B and C). Steviol glucuronide was excreted primarily in the urine of the subjects during 4 
the 72 hours collection period, accounting for 59 % and 62 % of the rebaudioside A and stevioside 5 
doses, respectively. No steviol glucuronide was detected in feces but steviol in the feces accounted for 6 
4.8 % and 5.2 % of rebaudioside A and stevioside, respectively. Pharmacokinetic analysis indicated 7 
that rebaudioside A and stevioside underwent similar metabolic and elimination pathways in humans 8 
with steviol glucuronide excreted primarily in the urine ad steviol in the feces. 9 
 10 
Table B: Summary of the mean (SD) pharmacokinetic data for steviol (Wheeler et al., 2008) 11 
 12 
Parameters (units) Treatment 
N Rebaudioside A N Stevioside 
Cmax (ng / ml) 1 227 (NA) 1 121 (NA) 
tMax (h) 1 72.0 (NA) 1 6.00 (NA) 
AUC0-t (ng h/ml) 0 NA (NA) 0 NA (NA) 
AUC0-inf  (ng h/ml) 0 NA (NA) 0 NA (NA) 
T½ (h) 0 NA (NA) 0 NA (NA) 
λ z (l/h)  0 NA (NA) 0 NA (NA) 
Aeu (0-72) (mg) 1 227 (NA) 1 121 (NA) 
CLR (L/h) 0 NA (NA) 0 NA (NA) 
AeF (0-72) (mg) 6 5.88 (6.95) 7 6.50 (7.08) 
NA = not applicable 13 
 14 
Table C: Summary of the mean (SD) pharmacokinetic data for steviol glucuronide (Wheeler 15 
et al., 2008) 16 
 17 
Parameters (units) Treatment 
N Rebaudioside A N Stevioside 
Cmax (ng / ml) 8 1588 (700) 8 2222 (1078) 
tMax (h) 8 12.0 (6.02, 24.0) 8 8.00 (6.00, 12.0) 
AUC0-t (ng h/ml) 8 33904 (15139) 8 39928 (20129) 
AUC0-inf  (ng h/ml) 4 46197 (18604) 4 53211 (23782) 
T½ (h) 4 14.8 (3.32) 4 14.0 (5.61) 
λ z (l/h)  4 0.0483 (0.00908) 4 0.0551 (0.0221) 
Aeu (0-72) (mg) 8 106 (24.0) 8 112 (36.87) 
CLR (L/h) 8 3.73 (2.01) 8 3.36 (2.51) 
AeF (0-72) (mg) 6 0 (0) 7 0 (0) 
tMax is presented as the Median (Min, Max) 18 
 19 
Conclusions: 20 
Administration of both rebaudioside A and stevioside to healthy human subjects results in substantial 21 
formation of steviol glucuronide systemically with very limited amounts of steviol observed. The 22 
pharmacokinetic analysis indicated that both rebaudioside A and stevioside were hydrolysed to steviol 23 
in the gastrointestinal tract prior to absorption. The majority of circulatory steviol was in the form of 24 
steviol glucuronide indicating rapid first-pass conjugation prior to urinary excretion (rebaudioside A: 25 
59%; stevioside: 62%). Only a small amount of steviol was detected in urine (rebaudioside A: 0.04%; 26 
stevioside: 0.02 %). The formation of steviol from stevioside was more rapid than that of rebaudioside 27 
A, which might be explained by the presence of an additional glucose moiety in rebaudioside A that 28 
must be removed prior to absorption as steviol in the colon. No meaningful differences were observed 29 
in the urinary recovery after administration of either rebaudioside A or stevioside. 30 
 31 
On the basis of the similarity in human metabolism to the primary metabolite steviol glucuronide 32 
following administration of rebaudioside A or stevioside through the classical phase II detoxification 33 
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mechanism, it can be concluded that previous human studies and rodent toxicological studies 1 
conducted with stevioside are relevant for assessing the human safety of rebaudioside A. 2 
 3 
4 
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ABBREVIATIONS 1 
ADI  Acceptable Daily Intake 2 
ADME  Absorption, distribution, metabolism and excretion 3 
ANS  Panel on Food Additives and Nutrient Sources Added to Food 4 
AUC  Area Under Curve 5 
BW  Body weight 6 
CAS  Chemical Abstract Service 7 
Cmax   Maximum observed plasma concentration. 8 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 9 
Chemical Abstract Service 10 
CHO  Chinese hamster ovary (cells) 11 
CoE  Council of Europe 12 
DNA  Deoxyribonucleic acid 13 
EC European Commission 14 
EFFA  European Flavour and Fragrance Association 15 
EFSA  The European Food Safety Authority 16 
EU  European Union 17 
FAO  Food and Agriculture Organization of the United Nations  18 
FEMA  Flavor and Extract Manufacturers Association 19 
FGE  Flavouring Group Evaluation  20 
FLAVIS (FL) Flavour Information System (database) 21 
HPLC   High Performance Liquid Chromatography 22 
GC-MS  Gas Chromatography-Mass Spectrometry 23 
ID   Identity 24 
IOFI  International Organization of the Flavour Industry 25 
IR   Infrared spectroscopy 26 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 27 
LD50  Lethal Dose, 50%; Median lethal dose 28 
LC-ESI-MS  Liquid Chromatography Electrospray Ionisation Tandem Mass Spectrometry  29 
MS  Mass spectrometry 30 
MSDI  Maximised Survey-derived Daily Intake 31 
mTAMDI Modified Theoretical Added Maximum Daily Intake 32 
NAD  Nicotinamide Adenine Dinucleotide  33 
NADP  Nicotinamide Adenine Dinucleotide Phosphate 34 
NMR  Nuclear Magnetic Resonance (NMR) 35 
No  Number 36 
NOAEL No Observed Adverse Effect Level 37 
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NOEL  No Observed Effect Level 1 
NTP  National Toxicology Program 2 
SCE  Sister Chromatid Exchange 3 
SCF  Scientific Committee on Food 4 
SMART  Somatic Mutation and Recombination Test  5 
TAMDI Theoretical Added Maximum Daily Intake 6 
TLC  Thin Layer Chromatography  7 
tMax   Time of maximum observed plasma concentration 8 
UDS  Unscheduled DNA Synthesis  9 
WHO  World Health Organisation   10 
